Clinical Trials in Pittsburgh

Showing 6841-6860 of 21,047 trials

Glyburide Advantage in Malignant Edema and Stroke Pilot

NCT01268683

The primary objective of this study is to assess the feasibility of enrolling, evaluating, and treating with glyburide for injection severe anterior circulation ischemic stroke participants, whether or not treated with standard of care intravenous (IV) recombinant tissue plasminogen activator (rtPA). Participants must be between 18-80 years of age, must have a baseline diffusion weighted image (DWI) lesion volume 82 -210 centimeters cubed (cm3), and time from symptom onset to start of study infusion must be ≤10 hour(hr). The secondary objectives are to assess the initial safety and tolerability, and pharmacokinetics (PK) /pharmacodynamics (PD) of glyburide in severe stroke participants, as well as to compare the clinical and magnetic resonance imaging (MRI) outcome data to benchmark data derived from published literature.

Ischemic Stroke

Remedy Pharmaceuticals, Inc.10 participantsStarted May 2011

Chicago, Illinois, United States • Baltimore, Maryland, United States • Boston, Massachusetts, United States +1 more locations

COMPLETEDPhase 4< 1 mile

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

NCT02216214

The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.

Overactive Bladder (OAB)

Astellas Pharma Global Development, Inc.888 participantsStarted Oct 2014

Huntsville, Alabama, United States • Mobile, Alabama, United States • Anchorage, Alaska, United States +117 more locations

Glyburide Advantage in Malignant Edema and Stroke Pilot

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

Find Trials by Condition in Pittsburgh

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

Alzheimer's Disease Neuroimaging Initiative 2

Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

Analysis of Both Sex and Device Specific Factors on Outcomes in Patients with Non-Ischemic Cardiomyopathy

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.

Novapak Prospective Observational Clinical Trial

Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder

Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

A Multi Center Study of Sexual Toxicities After Radiotherapy

Observational Study to Assess Migraine Prediction Tool

Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: a Cardiac MRI Study

Prospective, Multi-center, Single-arm Study of the Auryon Laser System for Treatment of Below-the-Knee (BTK) Arteries

Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial